Glucovance (Metformin Hydrochloride, Glibenclamide)

Glucovance is indicated for the management of hyperglycemia in patients with type 2 diabetes mellitus, particularly when diet, exercise, and monotherapy with either metformin or a sulfonylurea have not achieved adequate glycemic control.

• As adjunct therapy with diet and exercise to lower fasting and post‑prandial blood glucose levels.
• In combination with lifestyle modifications for patients who require additional glucose‑lowering effect beyond metformin alone.
• For adults who need both improved insulin sensitivity (metformin) and stimulated insulin secretion (glibenclamide).
• To simplify treatment regimens by providing two antidiabetic agents in one tablet.

The safety profile of Glucovance reflects the combined actions of metformin and glibenclamide, producing both typical gastrointestinal effects and hypoglycemia‑related reactions.

Common

• Nausea, abdominal discomfort, or diarrhea.
• Loss of appetite.
• Mild headache.
• Weight gain or mild fluid retention.

Serious

• Severe hypoglycemia with symptoms such as sweating, shakiness, confusion, or loss of consciousness.
• Lactic acidosis, a rare but life‑threatening condition characterized by rapid breathing and muscle pain.
• Allergic skin reactions including rash, itching, or swelling.
• Hepatic dysfunction indicated by jaundice or elevated liver enzymes.

When prescribing Glucovance, clinicians should evaluate patient history and monitor for conditions that may increase the risk of adverse events or reduce therapeutic effectiveness.

• Assess renal function before initiation and periodically, as metformin accumulation can occur in impaired kidneys.
• Use caution in patients with hepatic disease, heart failure, or a history of lactic acidosis.
• Monitor blood glucose closely to avoid hypoglycemia, especially when starting therapy or adjusting dose.
• Avoid use during pregnancy and lactation unless the potential benefit outweighs risks.
• Review concomitant medications that affect sulfonylurea metabolism or increase hypoglycemia risk.
• Adjust dose in elderly patients due to altered pharmacokinetics.

Glucovance may interact with several drugs that alter glucose metabolism, renal clearance, or sulfonylurea activity, requiring careful medication review.

Avoid

• Concurrent use with other sulfonylureas or meglitinides, which can potentiate hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that increase glibenclamide plasma levels.
• Iodinated contrast agents in patients with reduced renal function, due to risk of metformin‑associated lactic acidosis.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Diuretics or ACE inhibitors that affect renal function and electrolyte balance.
• Alcohol consumption, which can enhance metformin’s effect on lactate metabolism.